Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients - Seite 2

About MorphoSys

MorphoSys (FSE & NASDAQ: MOR) is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of exceptional, innovative therapies for patients suffering from serious diseases. The focus is on cancer. Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, of which 29 are currently in clinical development. In 2017, the first drug based on MorphoSys's antibody technology received regulatory approval. The Company's most advanced proprietary product candidate, MOR208, has been granted U.S. FDA breakthrough therapy designation for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Headquartered near Munich, Germany, the MorphoSys group, including the fully owned U.S. subsidiary MorphoSys US Inc., has approximately 330 employees. More information at https://www.morphosys.com.

HuCAL, HuCAL GOLD, HuCAL PLATINUM, CysDisplay, RapMAT, arYla, Ylanthia, 100 billion high potentials, Slonomics, Lanthio Pharma and LanthioPep are registered trademarks of the MorphoSys Group.

About Galapagos

Galapagos (Euronext & NASDAQ: GLPG) discovers and develops small molecule medicines with novel modes of action, three of which show promising patient results and are currently in late-stage development in multiple diseases. Our pipeline comprises Phase 3 through to discovery programs in inflammation, fibrosis, osteoarthritis and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at www.glpg.com.

Contact

Galapagos

Investors:

Elizabeth Goodwin

VP Investor Relations

[phone]

Sofie Van Gijsel

Director IR

[phone]

[e-mail]

 

Media:

Carmen Vroonen

Senior Director Communications & Public Affairs

[phone]

 

Evelyn Fox

Director Communications

[phone]

[e-mail]

 

MorphoSys AG

Dr. Sarah Fakih

Head of Corporate Communications & IR

 

Alexandra Goller

Director Corporate Communications & IR

 

Dr. Julia Neugebauer

Director Corporate Communications & IR

 

Dr. Verena Kupas